Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Current Breast Cancer Reports
Published in: Current Breast Cancer Reports 3/2012

01-09-2012 | Invited Commentary

Is HER2 Through?

Authors: George W. Sledge Jr., Lida Mina, Anna Maria Storniolo

Published in: Current Breast Cancer Reports | Issue 3/2012

Login to get access

Excerpt

While medical science never gives final answers, it often gives pretty good ones. Intellectual endeavors reach a point either where the science has answered the main questions or where, from a public health standpoint, the answers have addressed the public health problem in such a way that it simply isn’t worth devoting significant resources to the problem. …
Literature
1.
Arteaga C, Sliwkoowski M, Osborne C, et al. Treatment of HER2-positive breast cancer: current status and future perspectives. Nat Rev Clin Oncol. 2011;9:16–32.PubMedCrossRef
2.
Blackwell K, Burstein H, Storniolo A, et al. Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer. J Clin Oncol. 2010;28:1124–30.PubMedCrossRef
3.
Baselga J, Cortés J, Kim S, et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med. 2012;366:109–19.PubMedCrossRef
4.
Baselga J, Bradbury I, Eidtmann H, et al. Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomized, open-label, multicentre, phase 3 trial. Lancet. 2012;379:633–40.PubMedCrossRef
5.
Gianni L, Pienkowski T, Im Y, et al. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. Lancet Oncol. 2012;13:25–32.PubMedCrossRef
6.
Blackwell KL, Miles D, Gianni L, et al. Primary results from EMILIA, a phase III study of trastuzumab emtansine (T‐DM1) versus capecitabine (X) and lapatinib (L) in HER2‐positive metastatic breast cancer (MBC) previously treated with trastuzumab (T) and a taxane. J Clin Oncol. 2012;30 (suppl; abstr. LBA1).
Metadata
Title
Is HER2 Through?
Authors
George W. Sledge Jr.
Lida Mina
Anna Maria Storniolo
Publication date
01-09-2012
Publisher
Current Science Inc.
Published in
Current Breast Cancer Reports / Issue 3/2012
Print ISSN: 1943-4588
Electronic ISSN: 1943-4596
DOI
https://doi.org/10.1007/s12609-012-0080-x

Other articles of this Issue 3/2012

Current Breast Cancer Reports 3/2012 Go to the issue

Risk, Prevention, and Screening (MC Liu, Section Editor)

Comparison of Random Periareolar Fine Needle Aspirate versus Ductal Lavage for Risk Assessment and Prevention of Breast Cancer

Risk, Prevention, and Screening (MC Liu, Section Editor)

Clinical Perspective: Influence of Modifiable Lifestyle Factors, Body Weight, Physical Activity, and Alcohol on Breast Cancer Outcome

Risk, Prevention, and Screening (MC Liu, Section Editor)

Prophylactic Mastectomy and Risk-Reducing Salpingo-oophorectomy in BRCA1/2 Mutation Carriers

Risk, Prevention, and Screening (MC Liu, Section Editor)

Tamoxifen versus Raloxifene versus Exemestane for Chemoprevention

Risk, Prevention, and Screening (MC Liu, Section Editor)

Role of Mammography versus Magnetic Resonance Imaging for Breast Cancer Screening

Risk, Prevention, and Screening (MC Liu, Section Editor)

Options for Surgical Prophylaxis and Reconstruction
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits